Altimmune (ALT) Non-Current Assets (2010 - 2026)
Altimmune (ALT) posted quarterly Non-Current Assets of $954000.0 for Q1 2026, down 52.32% year-over-year from $2.0 million in Q1 2025, and down 45.08% quarter-over-quarter from $1.7 million in Q4 2025.
Altimmune (ALT) Non-Current Assets (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Non-Current Assets for 17 consecutive years, with $954000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 52.32% year-over-year to $954000.0; the TTM figure through Mar 2026 stood at $6.5 million (down 22.45% YoY), while the FY2025 annual figure was $1.7 million, down 15.35% from the prior year.
- Non-Current Assets declined to $954000.0 in Q1 2026 per ALT's latest filing, from $1.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $14.6 million in Q1 2022 and bottomed at $843000.0 in Q1 2024.
- Historically, Non-Current Assets has averaged $6.8 million across 5 years, with a median of $2.1 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 93.97% — and 2025, when it surged 137.37%.
- Altimmune's Non-Current Assets stood at $14.1 million in 2022, then plunged by 92.82% to $1.0 million in 2023, then soared by 102.37% to $2.1 million in 2024, then slipped by 15.35% to $1.7 million in 2025, then tumbled by 45.08% to $954000.0 in 2026.
- Business Quant data shows ALT's Non-Current Assets at $954000.0 in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 192.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.40 Mn |
| Mar 31, 2026 | 954,000.00 |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 843,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 13.61 Mn |
| Jun 30, 2023 | 13.78 Mn |
| Mar 31, 2023 | 13.97 Mn |
| Dec 31, 2022 | 14.12 Mn |
| Sep 30, 2022 | 14.27 Mn |
| Jun 30, 2022 | 14.40 Mn |
| Mar 31, 2022 | 14.57 Mn |
| Dec 31, 2021 | 14.74 Mn |
| Sep 30, 2021 | 18.64 Mn |